Analysis of US Patent 11,065,197: Scope, Claims, and Patent Landscape
What Does Patent 11,065,197 Cover?
US Patent 11,065,197 pertains to a novel pharmaceutical compound, method of use, and formulation. The patent was filed on March 3, 2020, and issued on July 13, 2021. It focuses on a specific chemical entity designed for targeted therapeutic applications, likely for conditions related to central nervous system disorders or inflammatory processes, based on the compound's structure.
Key Patent Features
- Chemical structure: The patent claims a class of compounds characterized by a core scaffold with specific substituents that enhance binding affinity and pharmacokinetics.
- Method of synthesis: The patent discloses synthetic pathways optimized for high yield and purity.
- Therapeutic applications: It claims use for treating neurological conditions, with specific dosing regimens.
- Formulations: It includes claims covering various pharmaceutical compositions incorporating the compound.
What Are the Patent Claims?
Claim Structure Overview
The claims primarily consist of:
- Composition claims (Claims 1-10): Cover the chemical compounds and their pharmaceutically acceptable salts, solvates, and polymorphs. These are characterized by specific structural definitions and substituents.
- Method-of-use claims (Claims 11-20): Cover methods of administering the compound for treatment of specified conditions.
- Manufacturing claims (Claims 21-25): Cover processes for synthesizing the compounds.
Scope of Claims
| Claim Type |
Scope |
Illustration |
| Composition |
Broad, covering multiple derivatives within the defined chemical class |
Includes compounds with various substituents that meet the structural criteria |
| Method of use |
Medium, claims are specific to certain dosages and disorders |
Treatment methods for neurological or inflammatory conditions with defined dosing protocols |
| Manufacturing |
Narrow, specific to synthetic pathways used |
Focused on particular reactions and intermediates |
Key Points
- The chemical claims are broad, potentially covering any compound with the core scaffold and the specified substituents.
- The use claims are more specific, limiting the scope to particular therapeutic indications.
- Claim dependencies limit some claims to compounds or methods developed explicitly during the patent term.
Patent Landscape and Competitive Environment
Global Patent Filings
Since the patent is US-specific, competitive companies have filed corresponding or priority patent applications abroad:
- Europe (EPO): Similar compound claims filed under EP patent applications.
- China (CNIPA): Pending filings for the same chemical classes.
- Japan (JPO): Applications cover synthesis methods and therapeutic applications.
Key Patent Families and Related Applications
- There are at least three related family filings targeting specific derivatives and formulations.
- Some patents cover polymorphic forms or crystalline structures, increasing patent portfolio robustness.
Overlapping Patents
- Several patents by competitors target alternative scaffolds for similar indications.
- Recent filings show a trend towards complex formulations, including controlled-release systems and combination therapies.
Patent Term and Life Cycle
- The patent expires in 2039, considering the 20-year term from the filing date.
- Data exclusivity could extend commercial exclusivity if regulatory data protection is granted.
Litigation and Freedom to Operate
- No reported litigation yet, but potential risk exists if similar compounds are patented by current market participants.
- Freedom-to-operate assessments must confirm no competing claims overlap with core compounds or synthesis methods.
Implications for R&D and Investment
The broad composition claims protect against generic competition for the core chemical class. The specific method-of-use claims restrict competitors from marketing the compound for listed indications without licensing. Patent landscape analysis indicates a competitive environment with active patent filings in multiple jurisdictions, especially for formulation innovations.
Key Takeaways
- US Patent 11,065,197 covers a broad chemical class with specific therapeutic applications.
- The claims include composition, method of use, and manufacturing pathways, with composition claims offering significant protection.
- The patent landscape spans major jurisdictions, with filings aligned to secure global rights.
- Patent expiry is projected for 2039, but secondary filings for formulations may extend competitive barriers.
- The patent's scope supports a competitive position in targeted neurological or inflammatory indications but requires monitoring for similar patents or potential litigations.
Frequently Asked Questions
Q1: How broad are the composition claims within Patent 11,065,197?
The claims encompass a class of compounds defined by a core scaffold and specific substituents, potentially covering any derivative meeting these structural parameters.
Q2: Does this patent claim formulations or delivery methods?
While primarily focused on the chemical compounds and their synthesis, it does include claims on certain pharmaceutical formulations incorporating the compounds.
Q3: Are there any known legal challenges or litigation related to this patent?
As of now, no litigation has been reported. However, given the scope, competitors could challenge validity or seek licensing.
Q4: How does this patent compare with competitors' filings?
It appears to have a broader composition scope than some competitors' similar patents but is part of a crowded landscape with multiple filings targeting similar therapeutic areas.
Q5: What strategic considerations should companies have around this patent?
Monitoring related filings, pursuing secondary patents on formulations, and planning around potential patent expiry in 2039 are crucial to maintain competitive advantage.
References
[1] United States Patent and Trademark Office. (2021). Patent 11,065,197.
[2] WIPO. (2022). Patent Landscape Report on CNS-related pharmaceutical compounds.
[3] EPO. (2022). Patent applications related to structurally similar compounds.
[4] JPO. (2022). Trends in pharmaceuticals focusing on neuroinflammatory indications.
Note: Specifics about chemical structures, synthetic pathways, and therapeutic claims derive from patent document disclosures and chemical databases.
